semaglutide spray NASAL SPRAY: A NEWS? OR A FAKE NEWS? The China Center for Drug Evaluation (CDE) announced that Shiling Pharma's semaglutide nasal has been approved for clinical trials for… SELANK NASAL SPRAY – Research

For example, investigational conjugates, such as AMG-133, which combine GLP-1 agonism with GIPR antagonism, demonstrated notable weight loss (~14% at 12 weeks) with preserved glycemic control and favorable tolerability in early-phase trials [46]

Studies have shown an average weight loss of 15% of body weight over 26-30 weeks, especially for people with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher and obesity-related health issues like type 2 diabetes

Have you been considering bariatric surgery

Hair thinning may reflect telogen effluvium from rapid weight loss or a direct drug effect, consistent with alopecia reported with licensed GLP-1 receptor agonists such as semaglutide